Step inside the World’s Newest Cholangiocarcinoma Research Lab – Saha Laboratory
Supriya K Saha, MD, PhD
- Assistant Member, Fred Hutchinson Cancer Research Center Human Biology & Clinical Research Divisions
- Assistant Professor, University of Washington Medical Center Department of Medicine, Division of Oncology
Fred Hutchinson Cancer Research Center, Seattle, Washington
2 postdoctoral fellows, 1 laboratory manager
Our laboratory seeks to identify and characterize new treatment strategies for cholangiocarcinoma, and to translate our laboratory findings into innovative clinic trials that improve the lives of our patients.
Dr. Saha’s work on cholangiocarcinoma has been recognized by the National Institutes of Health (NIH) and published in major scientific journals, including Nature.
He was also the recipient of a $60,000 Conquer Cancer Foundation Young Investigator Award funded by the Cholangiocarcinoma Foundation (CCF).
Message to Patients:
The generous support I received from the Cholangiocarcinoma Foundation as an early investigator was truly critical in my decision to dedicate my career to tackling this disease.
I am thrilled to have the opportunity to establish a new laboratory and clinical research program devoted to cholangiocarcinoma research at the Fred Hutchinson Cancer Research Center in Seattle. We hope our work will expand and accelerate the significant progress we have seen over the last few years for patients diagnosed with this disease.
Cholangiocarcinoma Foundation Sees Great Promise in New Research Lab
CCF Funded Research
- 2013 Conquer Cancer Young Investigator Award
- Mutant IDH Inhibits HNF-4a to Block Hepatocyte Differentiation and Promote Biliary Cancer
- Goal: To develop animal models, including gene mutations, to better understand cholangiocarcinoma in humans
Cholangiocarcinoma Research Publications
- Goyal L*, Saha SK*, Liu LY, Siravegna G, Leshchiner I, Ahronian LG, Lennerz JK, Vu P, Deshpande V, Kambadakone A, Mussolin B, Reyes S, Henderson L, Sun JE, Van Seventer EE, Gurski JM Jr, Baltschukat S, Schacher-Engstler B, Barys L, Stamm C, Furet P, Ryan DP, Stone JR, Iafrate AJ, Getz G, Porta DG, Tiedt R, Bardelli A, Juric D, Corcoran RB, Bardeesy N, Zhu AX. (2017). Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion-Positive Cholangiocarcinoma. Cancer Discovery, 7:252-263. *These authors contributed equally.
- Saha SK, Gordan JD, Kleinstiver BP, Vu P, Najem MS, Yeo J, Shi L, Kato Y, Levin RS, Webber JT, Damon LJ, Egan RK, Greninger P, McDermott U, Garnett MJ, Jenkins RJ, Rieger-Christ KM, Sullivan TB, Hezel AF, Liss AS, Mizukami Y, Goyal L, Ferrone CR, Zhu AX, Joung JK, Shokat KM, Benes CH, Bardeesy N. (2016). Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC-dependence in intrahepatic cholangiocarcinoma. Cancer Discovery, 6:727-39.
- Saha SK, Zhu AX, Fuchs CS, Brooks GA. (2016). Forty-Year Trends in Cholangiocarcinoma Incidence in the United States: Intrahepatic Disease on the Rise. Oncologist, 21:594-9.
- Saha SK*, Parachoniak CA*, Ghanta KS, Fitamant JF, Ross KN, Najem MS, Gurumurthy S, Akbay EA, Sia D, Cornella H, Miltiadous O, Walesky C, Desphande V, Zhu AX, Hezel AF, Yen K, Straley K, Travins J, Popovici-Muller J, Gliser C, Ferrone CR, Apte U, Llovet JM, Wong KK, Ramaswamy S, Bardeesy N. (2014). Mutant IDH inhibits HNF4a to block hepatocyte differentiation and promote biliary cancer. Nature, 513:110-4. *These authors contributed equally.